Silence Therapeutics (SLN) announced that Craig Tooman, who has served as the company’s president, CEO and board member since 2022, agreed by mutual consent to end his employment with the company effective December 14. Iain Ross, chairman of the Silence Board, will lead the company with immediate effect on an interim basis. Additionally, James Ede Golightly, a former Silence non-executive director, has been re-appointed to the company’s board of directors. An additional appointment of an US-based board member is anticipated in due course.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLN:
- Silence Therapeutics Reports Q3 2025 Financial Results
- Buy Rating Reaffirmed for Silence Therapeutics Amid Strong RNAi Pipeline and Financial Position
- Silence Therapeutics reports Q3 EPS (15c), consensus (21c)
- Silence Therapeutics Completes Enrollment for Phase 2 Study
- Silence Therapeutics completes patient enrollment in SANRECO